Publications

Mark J.C. Nuijten.  Early phase value scan for biotechnology innovation. Vol 1. May 2017: 159-164.

Mark J.C. Nuijten, Marja H. Pronk, John Hutton, Peter van Hasselt, Cor Oosterwijk and Frans F.H. Rutten. Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases.  The EuroBiotech Journal. 132. Vol. 1.  May 2017.

J. Naberhuis, V, Hunt, JD Bell. JS Partridge. S. Goates and M.J.C. Nuijten. Health care costs matter: a review of nutrition economics – is there a role for nutritional support to reduce the cost of medical care? Nutrition and Dietary  Supplements. May. 2017. 17.1-9.

Nuijten MJC, Vis J. J valuation and valuation of innovative medicinal productsRare Dis Res Treat. (2016) 2(1): 1-11

MJ Nuijten, J Vis. The Evaluation of Innovative Drugs Applying Business Valuation Concepts. Value in Health. 2016: November; 18.A504.

MJC Nuijten, J. Vis. The evaluation of ultra-innovative drugs: a broader perspective, Value & Outcomes Spotlight. Health Policy July – August 2016.  10-12.

Fugel HJ, Nuijten M, Postma M. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment. N Biotechnol. 2016 Sep 21;33(6):860-867. doi: 10.1016/j.nbt.2016.09.003.

Schwander B, Hiligsmann M, Nuijten M, Evers S. Systematic review and overview of health economic evaluation models in obesity prevention and therapy. Expert Rev Pharmacoecon Outcomes Res. 2016 Sep 9:1-10.

Nuijten MJ, Keller JJ, Visser CE, Redekop K, Claassen E, Speelman P, Pronk MH. Cost-effectiveness in Clostridium difficile treatment decision-making. World J Clin Cases. 2015 Nov 16;3(11):935-41. doi: 10.12998/wjcc.v3.i11.935.

Nuijten M. Health Economics in Medical Nutrition: An Emerging Science. Nestle Nutr Inst Workshop Ser. 2015;82:129-41. doi: 10.1159/000382009. Epub 2015 Oct 20. PMID: 26545115

Nuijten MJ, Krol M, Redekop WK. How to Handle Levels of Evidence In Health Economic Modelling. Value Health. 2015 Nov;18(7):A696. doi: 10.1016/j.jval.2015.09.2593.

Naberhuis JK, Bell JD, Goates S, Nuijten M. Global Publication Trends in Medical Nutrition Health Economics. Value Health. 2015 Nov;18(7):A553. doi: 10.1016/j.jval.2015.09.1780. Epub 2015 Oct 20.

Bruyère F, Buendia-Jiménez I, Cosnefroy A, Lenoir-Wijnkoop I, Tack I, Molinier L, Daudon M, Nuijten MJ. Urinary tract infections: Economical impact of water intake. Prog Urol. 2015 Sep;25(10):590-7. doi: 10.1016/j.purol.2015.05.010. Epub 2015 Jun 27. French.

Lenoir-Wijnkoop I, van der Beek EM, Garssen J, Nuijten MJ, Uauy RD. Health economic modeling to assess short-term costs of maternal overweight, gestational diabetes, and related macrosomia - a pilot evaluation. Front Pharmacol. 2015 May 20;6:103. doi: 10.3389/fphar.2015.00103. eCollection 2015.


Mark Nuijten. The Potential Impact of Current and Future Pharmaceutical Policy Changes on Cash Flows for Innovative Medicines. The Journal of Private Equity Vol. 18, No. 1 (WINTER 2014), pp. 34-45

M. Nuijten, A. Rudakova, T. Marshall. Health economic evaluation of paricalcitol and combination of cinacalcet  with non-selective vitamin D in patients with chronic kidney disease in Russian Federation. 2014. ISSN 1561_6274 .616.61-036.92-08.857-0612(471)

Bruyère F, Buendia-Jiménez I, Cosnefroy A, Lenoir-Wijnkoop I, Tack I, Molinier L, Daudon M, Nuijten MJ. [Urinary tract infections: Economical impact of water intake]. Prog Urol. 2015 Sep;25(10):590-7. doi: 10.1016/j.purol.2015.05.010. Epub 2015 Jun 27. French.

Lenoir-Wijnkoop I, van der Beek EM, Garssen J, Nuijten MJ, Uauy RD. Health economic modeling to assess short-term costs of maternal overweight, gestational diabetes, and related macrosomia - a pilot evaluation. Front Pharmacol. 2015 May 20;6:103. doi: 10.3389/fphar.2015.00103. eCollection 2015.

Nuijten MJ, Dubois DJ, Joseph A, Annemans L. Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands. Front Pharmacol. 2015 Apr 14;6:67. doi: 10.3389/fphar.2015.00067. eCollection 2015.

Nuijten M, Roggeri DP, Roggeri A, Novelli P, Marshall TS. Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected]. Clin Drug Investig. 2015 Apr;35(4):229-38. doi: 10.1007/s40261-014-0264-4.

Freijer K, Lenoir-Wijnkoop I, Russell CA, Koopmanschap MA, Kruizenga HM, Lhachimi SK, Norman K, Nuijten MJ, Schols JM. The view of European experts regarding health economics for medical nutrition in disease-related malnutrition.Eur J Clin Nutr. 2015 May;69(5):539-45. doi: 10.1038/ejcn.2014.280. Epub 2015 Jan 21.

Fugel HJ, Connolly M, Nuijten M. An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practices. BMC Health Serv Res. 2014 Oct 9;14:482. doi: 10.1186/1472-6963-14-482.

Mark Nuijten. Pitfalls in the Valuation of a Pharmaceutical Company. Journal of Private Equity. Fall 2013, Vol. 16, No. 4: pp. 57–66

Mark Nuijten and Marja Pronk. Financial Valuation Algorithm for the Assessment
of the Future Sales of a New, Innovative Medicinal Product. The Journal of Private Equity. Summer 2014, Vol. 17, No. 3: pp. 35-44. DOI: 10.3905/jpe

Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H. Health economics evidence for medical nutrition: are these interventions value for money in integrated care? Clinicoecon Outcomes Res. 2014 May 19;6:241-52. doi: 10.2147/CEOR.S58852. eCollection 2014. Review.

Fugel HJ, Nuijten M, Faulkner E. The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions. J Med Econ. 2014 May;17(5):305-11. doi: 10.3111/13696998.2014.902842. Epub 2014 Mar 21.PMID: 24654841 [PubMed - in process]

Walzer S, Droeschel D, Nuijten M, Chevrou-Séverac H. Health economic analyses in medical nutrition: a systematic literature review. Clinicoecon Outcomes Res. 2014 Mar 10;6:109-24.

Lenoir-Wijnkoop I, Nuijten MJ, Craig J, Butler CC. Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea. Front Pharmacol. 2014 Feb 17;5:13.

Liedgens H, Obradovic M, Nuijten M. Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res. 2013 Nov 25;5:597-609.

Freijer K, Bours MJ, Nuijten MJ, Poley MJ, Meijers JM, Halfens RJ, Schols JM. The economic value of enteral medical nutrition in the management of disease-related malnutrition: a systematic review. J Am Med Dir Assoc. 2014 Jan;15(1):17-29. doi: 10.1016/j.jamda.2013.09.005. Epub 2013 Nov 13.

Walzer S, Nuijten M, Wiesner C, Kaier K, Johansson PO, Oertel S. Microeconomic surplus in health care: applied economic theory in health care in four European countries. Front Pharmacol. 2013 Feb 18;4:17. doi: 10.3389/fphar.2013.00017. eCollection 2013.

Fugel HJ, Nuijten M, Postma M. Stratified medicine and reimbursement issues. Front Pharmacol. 2012;3:181. doi: 10.3389/fphar.2012.00181. Epub 2012 Oct 15.

Lotan Y, Jiménez IB, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ. Increased Water Intake as a Prevention Strategy for Recurrent Urolithiasis: Major Impact of Compliance on Cost-Effectiveness.J Urol. 2012 Sep 24. doi:pii: S0022-5347(12)04971-3. 10.1016/j.juro.2012.08.254.

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S. Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. Clinicoecon Outcomes Res. 2012;4:237-43. doi: 10.2147/CEOR.S34371.

Lenoir-Wijnkoop I, Nuijten MJ, Gutiérrez-Ibarluzea I, Hutton J, Poley MJ, Segal L, Bresson JL, van Ganse E, Jones P, Moreno L, Salminen S, Dubois D. Workshop Report: concepts and methods in the economics of nutrition--gateways to better economic evaluation of nutrition interventions. Br J Nutr. 2012 Nov 14;108(9):1714-20. doi: 10.1017/S0007114512003704.

Freijer K, Tan SS, Koopmanschap MA, Meijers JM, Halfens RJ, Nuijten MJ. The economic costs of disease related malnutrition. Clin Nutr. 2013 Feb;32(1):136-41. doi: 10.1016/j.clnu.2012.06.009.

Lotan Y, Buendia Jiménez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. BJU Int. 2012 Dec;110(11 Pt C):E1060-7.

Freijer K, Nuijten MJ, Schols JM. The budget impact of oral nutritional supplements for disease related malnutrition in elderly in the community setting. Front Pharmacol. 2012;3:78. doi: 10.3389/fphar.2012.00078. Epub 2012 May 4.

Nuijten MJ, Brignone M, Marteau F, den Boer JA, Hoencamp E. Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting. Clin Ther. 2012 Jun;34(6):1364-78. doi: 10.1016/j.clinthera.2012.04.006. Epub 2012 May 11.

Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, Grossi F, Bischoff H, Heigener D, Walzer S. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 2012 Jun;76(3):465-71. doi: 10.1016/j.lungcan.2011.11.005.

Macedo A, Andrade S, Mulchande M, Marx SE, Nuijten M. Estudo de Avaliação do Custo-Efectividade da Utilização de Paricalcitol. no Tratamento de Doentes com Insuficiência Renal Terminal e Hiperparatiroidismo Secundário em Portugal Rev Port Farmacoter. 2011;3:75-86.

Nuijten MJ, Aultman R, Carpeño JD, Vergnenègre A, Chouaid C, Walzer S, Siebert U. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Curr Med Res Opin 2011; PMID: 21970659.

Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria. Pediatr Infect Dis J 2011; PMID: 21960187

Nuijten M, Lenoir-Wijnkoop I. Nutrition economics: An innovative approach to informed public health management. Eur J Pharmacol 2011;  PMID: 21810421

Nuijten MJ, Dubois DJ. Cost-utility analysis: current methodological issues and future perspectives. Front Pharmacol 2011; 2 (): 29. PMID: 21713127

Nuijten MJ, Van Gelder PH. Concise Equation That Captures the Essential Elements of One-Way Sensitivity Analyses in Health Economic Models. Med Decis Making 2011;  (): PMID: 21252378

Nadine van Dongen, Mark JC Nuijten. IP Data for Health Economic Modelling: An Alternative Data Source. ISPOR Connections. March/April 2011 Vol. 17. No 1;8-10.

Mark Nuijten, Thomas Mittendorf, Ulf Persson, and Christa Boer. Few Practical Issues for the conduct of Budget Impact analysis (BIA). ISPOR Connections. January/February 2011 Vol. 17. No 1;12-13.

Lenoir-Wijnkoop I, van Aalderen WM, Boehm G, Klaassen D, Sprikkelman AB, Nuijten MJ. Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands. Eur J Health Econ 2010;  (): .PMID: 21165666.

Nuijten MJC. Vergoeding van geneesmiddelen. De anesthesioloog. N. 4. 2010. 16-18.

Nuijten MJC. Studie toont aan: medische voeding werkt kostenbesparend. @live, April 2010. 12-13.

Freijer K, Nuijten MJ. Analysis of the health economic impact of medical nutrition in the Netherlands. Eur J Clin Nutr 2010; 64 (10): 1229-34.

Nadine van Dongen, Mark JC Nuijten. Application of PIP data in health economic models for market access.  Dovepress Journal: Patient Intelligence. Published Date November 2010, Volume 2010:2(Default). Pages 53-58. DOI 10.2147/PI.S15007.

Mickisch GH, Escudier B, Walzer S, Nuijten M. Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. Br J Cancer 2010; 103 (8): 1309-10.

Nuijten M, Heigener DF, Bischoff HG, Chouaid C, Vergnenègre A, de Castro Carpeño J, Aultman R, Walzer S, Siebert U. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010; 69 Suppl 1 (): S4-10.

Bischoff HG, Heigener DF, Walzer S, Nuijten M. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 2010; 69 Suppl 1 (): S18-23.    

Lenoir-Wijnkoop I, Dapoigny M, Dubois D, van Ganse E, Gutiérrez-Ibarluzea I, Hutton J, Jones P, Mittendorf T, Poley MJ, Salminen S, Nuijten MJ. Nutrition economics - characterising the economic and health impact of nutrition. Br J Nutr 2010;  (): 1-9.

Nuijten MJC. Studie toont aan: medische voeding werkt kostenbesparend. @live, April 2010. 12-13.

Freijer K, Nuijten MJ. Analysis of the health economic impact of medical nutrition in the Netherlands. Eur J Clin Nutr 2010; 64 (10): 1229-34.

Nuijten M, Andress DL, Marx SE, Curry AS, Sterz R. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig 2010; 30 (8): 545-57.

Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther 2010; 32 (4): 717-28.

Nuijten MJ, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. Eur J Health Econ 2010;  (DOI: 10.1007/s10198-010-0236-4.

Ritchie M, Liedgens H, Nuijten M. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis. Clin Drug Investig 2010; 30 (2): 71-87.

Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010; 11 (1): 105-15.

Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010; 102 (1): 80-6.

Nuijten M, Mickisch G. SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival. Br J Cancer 2010; 102 (1): 232-3; author reply 234-5.

Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010; 11 (1): 105-15.

Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009; 12 (4): 291-300.

Mark JC Nuijten. Verlenging patentperiode kan oplossing zijn. Dossier Beschikbaarheid. Nefarma. 2009. September. Page 7.

Mark Nuijten en Eline Kogels. De toenemende hindernissen in het vergoedingstraject en de markttoegang van nieuwe, innovatieve geneesmiddelen. Nefarma. 2009. September.

Voorschuur A, Leufkens B, Schuurman A, Nuijten MJC. Dossier Beschikbaarheid. Nefarma. 2009. September.

Eline Kogels, Mark Nuijten. The Emerging Hurdles For Reimbursement And Market Access For New Innovative Pharmaceuticals. ISPOR Connections. September-October 2009: Vol.15 (5); 7-9.

Mark Nuijten, Eline Kogels. The Appropriateness of Prescription Restrictions as a Policy Tool. ISPOR Connections.  January/February 2009. Vol 15. (1); 8-10.

Mittendorf T, Briggs A, Bastida J L, Nuijten M & Persson U. Do Health Politicians Really Listen to Health Economists? - Observations from Europe. ISPOR Connections November/December 2009; 15(6): 15-16

Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009; 12 (4): 301-8.

Nuijten M, Andress DL, Marx SE, Sterz R. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009; 25 (5): 1221-34

Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective. Clin Drug Investig. 2008;28(9):583-601.

Resch B; Gusenleitner W; Nuijten M.J C; Lebmeier M.; Wittenberg W.. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clinical therapeutics 2008;30(4):749-60

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.Value Health. 2007 Sep-Oct;10(5):336-47.

Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics. 2007;25(1):55-71.

Dakin H, Nuijten M, Liedgens H, Nautrup BP. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom. Clin Ther. 2007 Jul;29(7):1491-507

Nuijten MJ. Pricing matrix model: dealing with uncertainty. Eur J Health Econ. 2007 Dec;8(4):333-7. Epub 2007 Jan 13.

M.J.CNuijten, M. Al, F. Rutten.   Inter-variable Uncertainty in Decision Analytic Modelling. The concept of second-order sensitivity. Estudios de Economía Aplicada, 2006: 711-730 • Vol. 24-3.

Nuijten MJC, Poulsen Nautrup B, Liedgens H. Oral fixed drug combination analgesic tramadol/paracetamol: benefits for patients and budgets. Expert Rev. Pharmacoeconomics Outcomes Res. 6(2), 113–121 (2006).

Sittl R, Nuijten M, Nautrup BP.Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther. 2005 Jul;27(7):1022-31.

Nuijten MJC.  Poulsen-NautrupB. Economic evaluation of a tramadol/paracetamol combination vs. tramadol in subacute low back pain in The Netherlands.   Journal of Applied Therapeutic Research. 2005; 5(4) 17-28.

Liedgens H. Nuijten MJC, Poulsen Nautrup B. Economic Evaluation of Tramadol/Paracetamol Combination Tablets for Osteoarthritis Pain in The Netherlands. J Appl Ther Res. 2005; 25 (12): 785-802.

Nuijten MJC. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics. 2005;23(8):851-3; 853.

Nuijten MJC, Kosa J Pricing of Pharmaceuticals. Assessing the Pricing Potential by a Pricing Matrix Model. Eur J Health Econom 2004; 5:110-115. 

Nuijten MJC. Are the Health Economic Guidelines Suitable for the Assessment of New Drugs in Children’s Diseases? Ispor Connections. 2004; Vol. 10. No 1: 4-5. 

Nuijten MJC. The Application of Free Market Theory to the Health Care Market. Eurohealth Winter 2003/2004; 9(4):13-17.

Nuijten MJC. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Pharmacoeconomics. 2004;22(12):759-69.

van Zanten ARH, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJC, Polderman KH   Importance of Nondrug Costs of Intravenous Antibiotic Therapy. Critical Care 2003; 7:R184-R199. 

Nuijten MJC, Szende A, Kosa J et al. Health care reform in six Central European countries. A focus on health economic requirements in the drug and reimbursement process. Eur. J. Economics. 2003; 4: 286-291.

Nuijten MJC. Betrouwbaarheid gezondheidseconomische modellen neemt toe. Conceptuur; 2003: 36: 11-13.

Nuijten MJC and Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics. 2003;21(13):941-50. Pharmacoeconomics. 2003;21(13):941-50

Nuijten MJC, Kosa J, Engelfriet P. Modeling the Cost-Effectiveness and Budgetary Impact for Subpopulations. European Journal of Health Economics 2003; 4:70-78. 

Nuijten MJC. In search for more confidence in health economic modelling (thesis). 2003.

M. J.C. Nuijten, G. L. Bakris, W. Wittenberg and J. Kosa. Modeling the clinical outcomes of Tarka in diabetic nephropathy. Am J Hypertens (2003) 16, 91–96; doi:S0895-7061(03)00316-9

Nuijten MJ, Villar FA, Kosa J, Nadipelli V, Rubio-Terres C, Suarez C. Related Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Value Health. 2003 Mar-Apr;6(2):126-36.

Nuijten MJC. Budgetbewaking wordt hartbewaking. De Stem/BN. 23 april 2003.

Nuijten MJC and Rutten F. Combining a Budgetary Impact Analysis and a Cost-Effectiveness Analysis Using Decision Analytic Modelling Techniques. PharmacoEconomics 2002;20(12):855-67.

Palmer CS, Nuijten MJC, Schmier JK, Subedi P, Snyder EH Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics. 2002;20(9):617-28.

Nuijten MJC, Berto P, Kosa J, Nadipelli V, Cimminiello C, Spreafico A.  Cost-effectiveness of enoxaparin as thromboprophylaxis in acutelly ill medical patients from the Italian NHS perspective. Recenti Prog Med. 2002 Feb;93(2):80-91.

Nuijten MJC, Berto P, Berdeaux G, Hutton J, Fricke F-U,  Villar FA. Trends in decision-making process for pharmaceuticals in Western European countries: A focus on emerging hurdles for obtaining reimbursement and a price. HEPAC 2; 2001; 4:162-169.

Nuijten MJC, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002 Jan-Feb;5(1):44-54.

Nuijten MJC, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics. 2001;19(10):1051-64.

Nuijten MJC, van Iperen P, Palmer C, van Hilten BJ, Snyder E.  Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health. 2001 Jul-Aug;4(4):316-28.

Nuijten MJC. Assessment of clinical guidelines for continuation treatment in major depression. Value Health. 2001 Jul-Aug;4(4):281-94.

J Hutton, M Nuijten and M Chambers. Single European-level cost-effectiveness analysis: over the fourth hurdle into the ditch? Value in Health. Volume 4, Issue 2, March 2001. 175.

Brown R, Hutton J, Nuijten M, Can unit costs be compared across Western European countries? Value in Health. Volume 4, Issue 2, page 48, March 2001.

J Hutton, M Nuijten and M Chambers. Internationally Applicable Economic Evaluation of Health Technologies: Reducing or Transferring the Burden. Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 2001; 17-18.

Van Barlingen H, Nuijten MJC, Volmer T, Sanderson D, Lacey LF. Model to evaluate the cost effectiveness of different antibiotics in the management of acute bacterial exacerbation of chronic bronchitis in Germany. (1998). Journal of Medical Economics. 1 : 201-218.

Van Barlingen H, Nuijten MJC, Volmer T, Sanderson D, Lacey LF. Model to evaluate the cost effectiveness of different antibiotics in the management of community-aquired pneumonia in Germany. (1998). Journal of Medical Economics. 1 : 247-261.

Pinto CG, Lafuma A, Fagnani F, Nuijten MJ, Berdeaux G. Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. Pharmacoeconomics. 2001;19(3):255-65.

De Smet PA, Bonsel G, Van der Kuy A, Hekster YA, Pronk MH, Brorens MJ, Lockefeer JH, Nuijten MJC.  Introduction to the pharmacoeconomics of herbal medicines. Pharmacoeconomics. 2000 Jul;18(1):1-7.

Nuijten MJC. Bridging decision analytic modelling with a cross-sectional approach. PharmacoEconomics. 2000,Mar: 17 (3): 227-236.

Nuijten MJC, McCormick J, Waibel F and Parison D. Economic evaluation of letrozole in the treatment of advanced breast cancer in post-menopausal women in Canada.  Value in Health. 2000, Volume 3; Number 1: 31-39.

Lecomte P, De Hert M, Van Dijk M, Nuijten MJC, Nuyts G, Persson U. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value in Health. 2000, Volume 3; Number 1: 1-11.

Nuijten MJC et al. Economic Evaluation in Health Care: ADIS. 1999, ((2 chapters).

Nuijten MJC. Pharmacoeconomics in European Decision-Making. Value in Health. 1999. 2(5): 319-322.

Nuijten MJC. Pharmacoeconomische gegevens binnenkort verlicht. Transmitter. 32-35.1999.

Nuijten MJC. Ziekte en zorg in kaart gebracht. Benders et alii, Pharmacare. 1998.

Nuijten MJC. Meester L, Waibel F, Wait S.  Cost-effectiveness of letrozole in the treatment of advanced breast cancer in post-menopausal women in the UK.  PharmacoEconomics.  1999; 16 (4): 379-97.

Nuijten, MJC. Hardens M. Measuring sensitivity in pharmacoeconomic studies: an integration of point-sensitivity and range-sensitivity: a refinement by incorporation of probability distributions.  PharmacoEconomics, 1999; 16 (1): 33-41.

Nuijten MJC, van der Kuy A. Een Markov-model analyse voor de bepaling van kosten en doeltreffendheid van een preventieve behandeling met SSRIs in depression (A Markov model simulation of the efficiency of a maintenance treatment with SSRIs in depression).  Pharmaceutisch Weekblad, 1999, 4: 124-129.

Nuijten MJC, Hadjadjeba L, Evans C, van den Berg J. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France.  PharmacoEconomics, October 1998, (4): 433-455.

MJC. Nuijten. The power of economic modeling. 1998. 10. The Lewin Group Review.

Nuijten MJC, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A. Reporting format for economic evaluation. Part II: Focus on modelling studies. Pharmacoeconomics. 1998 Sep;14(3):259-68.

Nuijten MJC, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A. Reporting format for economic evaluation. Part I: Application to the Dutch healthcare system. PharmacoEconomics, August; 14 (2): 1998; 159-163.

Nuijten MJC. Management Info. The Lewin Group vindt gehoor voor farmaco-economie. 1998: 5.

Nuijten MJC. The selection of data sources for use in modelling studies. PharmacoEconomics, March 1998; 3 (3): 305-316.

Nuijten MJC, Starzewski J.  Applications of Modeling Studies.  PharmacoEconomics, March 1998; 3 (3): 289-291.

Nuijten MJC.  Hardens M. Measuring sensitivity in pharmacoeconomics studies:  An integration of point-sensitivity and range-sensitivity”.  PharmacoEconomics, November 1997; 12 (5): 555-564.

Jansen R, Capri S, Nuijten MJC, et al. Economic evaluation of meloxicam (7.5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis:  A cross-national assessment for France, Italy and the United Kingdom.  British Journal of Medical Economics, 1997, Vol. 11: 9-22.

Louis-Touizer C, Nuijten MJC, Bayle F, Cantarovich D, Lang P, Lebranchu Y, Le Pogamp P, Touraine JL, Vialtel P, Monroe T, de Vries MJ. Economic contribution of mofetil mycofenolate as preventive immunosuppressive treatment after renal transplantation from cadaver. Presse Med. 1996 Nov 2;25(33):1577-82.

Jansen R, Burrell A, Nuijten MJC, Hardens M. “An economic evaluation of meloxicam (Mobic® ) versus diclofenac (Voltarol Redard® ) in the treatment of osteoarthritis in the United Kingdom”.  British Journal of Medical Economics, 1996, Vol. 10: 247-262.

Nuijten MJC, Hardens M, Souetre E. Cost-effectiveness of a maintenance treatment with citalopram in major depression:  A Markov process model.  PharmacoEconomics, 1995, 159-168.

Moonen LM, Horenblas S, van der Voet JC, Nuijten (published as Nuyten) MJ, Bartelink H. Bladder conservation in selected T1G3 and muscle-invasive T2-T3 bladder carcinoma using combination therapy of surgery and iridium-192 implantation. The British Journal of Urology, 1994,(74)322-327.

Horenblas S, Nuijten (published as Nuyten) MJC, Hoefnagel CA, Moonen LM, Delemarre JF.  The detection of lymph node invasion in prostatic carcinoma with ileopelvic lymphoscintigraphy. The British Journal of Urology, 1992,(9)180-182.

Moonen LM, Horenblas S, van der Voet JC, Nuijten (published as Nuyten) MJ, Bartelink H. The results of a treatment for muscle invasive bladder cancer combining surgery with interstitial radiotherapy using Iridium".  Het Nederlands Tijdschrift voor Geneeskunde (The Dutch Journal for Medicin), 1992,(33)1630.